Sichuan Hebang Biotechnology Co Ltd
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, and photovoltaic packaging … Read more
Sichuan Hebang Biotechnology Co Ltd (603077) - Total Assets
Latest total assets as of September 2025: CN¥29.29 Billion CNY
Based on the latest financial reports, Sichuan Hebang Biotechnology Co Ltd (603077) holds total assets worth CN¥29.29 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sichuan Hebang Biotechnology Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Sichuan Hebang Biotechnology Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sichuan Hebang Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sichuan Hebang Biotechnology Co Ltd's total assets of CN¥29.29 Billion consist of 47.2% current assets and 52.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.6% |
| Accounts Receivable | CN¥2.07 Billion | 7.0% |
| Inventory | CN¥4.54 Billion | 15.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.56 Billion | 8.6% |
| Goodwill | CN¥1.84 Billion | 6.2% |
Asset Composition Trend (2009–2024)
This chart illustrates how Sichuan Hebang Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sichuan Hebang Biotechnology Co Ltd's current assets represent 47.2% of total assets in 2024, an increase from 22.9% in 2009.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2024, up from 11.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 4.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 15.3% of total assets.
Sichuan Hebang Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Sichuan Hebang Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Renxin New Material Co. Ltd. A
SHE:301395
|
China | CN¥1.99 Billion |
|
Engro Corporation Ltd
KAR:ENGRO
|
Pakistan | PKRs765.68 Billion |
|
Fatima Fertilizer Company Ltd
KAR:FATIMA
|
Pakistan | PKRs256.23 Billion |
|
North Huajin Chemical Industries Co Ltd
SHE:000059
|
China | CN¥24.47 Billion |
|
Jiangsu Wujiang China Eastern Silk Market Co Ltd
SHE:000301
|
China | CN¥212.80 Billion |
|
Zangge Holding Co Ltd
SHE:000408
|
China | CN¥16.36 Billion |
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
China | CN¥2.53 Billion |
|
Jilin Gpro Titanium Industry Co Ltd
SHE:000545
|
China | CN¥2.48 Billion |
Sichuan Hebang Biotechnology Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sichuan Hebang Biotechnology Co Ltd generates 0.29x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sichuan Hebang Biotechnology Co Ltd generates $ 0.11 in net profit.
Sichuan Hebang Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.07 | 1.88 | 1.05 |
| Quick Ratio | 2.11 | 1.03 | 0.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥8.81 Billion | CN¥ 5.07 Billion | CN¥ 165.62 Million |
Sichuan Hebang Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sichuan Hebang Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.11 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 20.8% |
| Total Assets | CN¥29.65 Billion |
| Market Capitalization | $2.27 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sichuan Hebang Biotechnology Co Ltd's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sichuan Hebang Biotechnology Co Ltd's assets grew by 20.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sichuan Hebang Biotechnology Co Ltd (2009–2024)
The table below shows the annual total assets of Sichuan Hebang Biotechnology Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥29.65 Billion | +20.81% |
| 2023-12-31 | CN¥24.54 Billion | +1.82% |
| 2022-12-31 | CN¥24.10 Billion | +34.48% |
| 2021-12-31 | CN¥17.92 Billion | +21.59% |
| 2020-12-31 | CN¥14.74 Billion | +1.77% |
| 2019-12-31 | CN¥14.48 Billion | +9.01% |
| 2018-12-31 | CN¥13.29 Billion | +1.36% |
| 2017-12-31 | CN¥13.11 Billion | +1.40% |
| 2016-12-31 | CN¥12.93 Billion | +15.45% |
| 2015-12-31 | CN¥11.20 Billion | +22.62% |
| 2014-12-31 | CN¥9.13 Billion | +63.59% |
| 2013-12-31 | CN¥5.58 Billion | +10.62% |
| 2012-12-31 | CN¥5.05 Billion | +37.05% |
| 2011-12-31 | CN¥3.68 Billion | +18.06% |
| 2010-12-31 | CN¥3.12 Billion | -1.52% |
| 2009-12-31 | CN¥3.17 Billion | -- |